Immunologic Factors: all 3,292 studies that test it
Page 18 of 33. Open to participants first (386), then studies with results posted, then the rest; newest registration first within each.
- Individualized Dose Study of ATG in Haploidentical Hematopoietic Stem Cell TransplantationStatus unknownNCT04778618Phase 2
- Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe HemoglobinopathiesWithdrawnNCT04776850Early Phase 1
- DARA RVD For High Risk SMMActive, not recruitingNCT04775550Phase 2
- Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT04765111Phase 2
- The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple MyelomaStatus unknownNCT04762745Phase 1/2
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell LymphomaActive, not recruitingNCT04739813Phase 1
- Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE)CompletedNCT04733040Phase 2
- Subcutaneous Immunoglobulin for Myasthenia GravisCompletedNCT04728425Phase 2
- PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AMLStatus unknownNCT04722952Phase 3
- Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM PatientsActive, not recruitingNCT04717700Phase 2
- A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular LymphomaActive, not recruitingNCT04712097Phase 3
- Sargramostim (GM-CSF) + PD-1WithdrawnNCT04703426Phase 2
- Intravenous Immunoglobulin and Prednisolone for RPL After ART.CompletedNCT04701034Phase 2
- Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple SclerosisActive, not recruitingNCT04688788Phase 3
- Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.CompletedNCT04688151Phase 1
- CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.Active, not recruitingNCT04667663Phase 1
- Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMMActive, not recruitingNCT04653246Phase 2
- Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB)CompletedNCT04643587Phase 1
- Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency DiseasesActive, not recruitingNCT04640142Phase 3
- Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell LymphomaWithdrawnNCT04635683Phase 1
- Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's MacroglobulinemiaActive, not recruitingNCT04624906Phase 2
- IVIG in Patients With Severe COVID-19 Requiring Mechanical VentilationStatus unknownNCT04616001Phase 4
- Open-label Trial of IVIG in Children With PANSCompletedNCT04609761Phase 2
- Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS LymphomaActive, not recruitingNCT04609046Phase 1
- Lenalidomide and Low-dose Cyclophosphamide for MALT LymphomaStatus unknownNCT04604028Phase 2
- A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCLActive, not recruitingNCT04594798Phase 2
- Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune ThrombocytopeniaStatus unknownNCT04588194Phase 2
- Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Idiopathic Nephrotic Syndrome.Status unknownNCT04585152Phase 2
- Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous TransplantWithdrawnNCT04584307Phase 2
- Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS DiseaseActive, not recruitingNCT04578639Phase 3
- CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell LymphomaCompletedNCT04578600Phase 1
- Pomalidomide Treatment in Patients With Kaposi SarcomaActive, not recruitingNCT04577755Phase 2
- Intravenous Immunoglobulins for the Treatment of Covid-19 Patients: a Clinical TrialStatus unknownNCT04548557Phase 3
- A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological MalignanciesActive, not recruitingNCT04547049Phase 3
- Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell LymphomaStatus unknownNCT04544059Phase 2
- Comparative Study of Dietary and Immunological Management of Refractory Epilepsy in ChildrenStatus unknownNCT04542629Phase 4
- Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS PatientsSuspendedNCT04539236Phase 1/2
- COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;CompletedNCT04534725Phase 3
- Rituximab and RASi in Patients with IgANCompletedNCT04525729Phase 4
- Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain CancerWithdrawnNCT04521946Phase 1
- Sintilimab and Lenalidomide as a Treatment for CAEBVStatus unknownNCT04518982Phase 2
- MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)CompletedNCT04509791Phase 2
- Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot TrialStatus unknownNCT04507477Phase 1/2
- Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin LymphomaTerminatedNCT04502706Phase 1
- Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex TreatmentCompletedNCT04500067Phase 3
- A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or LenalidomideActive, not recruitingNCT04497961Phase 2
- Rituximab for Idiopathic Nephrotic SyndromeCompletedNCT04494438Phase 3
- Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AMLStatus unknownNCT04490707Phase 3
- Rituximab in Chronic Inflammatory Demyelinating PolyneuropathyWithdrawnNCT04480450Phase 2
- Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated LymphomaActive, not recruitingNCT04479267Phase 2
- Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)Active, not recruitingNCT04474223Phase 3
- Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis OnsetActive, not recruitingNCT04466150Phase 4
- Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT04460248Phase 2
- Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT04458610Phase 2
- Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial)WithdrawnNCT04450654Phase 2
- An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to TreatmentActive, not recruitingNCT04447716Phase 1
- LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)Active, not recruitingNCT04446962Phase 1/2
- VR-CAP in the First-line Treatment for Patients With Marginal Zone LymphomaCompletedNCT04433156Phase 2
- Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell LymphomaStatus unknownNCT04432402Not applicable
- Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19)CompletedNCT04432324Phase 2
- Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent LymphomaTerminatedNCT04431635Phase 1
- Lenalidomide in Combination With CHOP in Patients With Untreated PTCLStatus unknownNCT04423926Phase 1/2
- Convalescent Antibodies Infusion in COVID 19 PatientsWithdrawnNCT04418531Not applicable
- A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone LymphomaActive, not recruitingNCT04416451Phase 2
- NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILUREStatus unknownNCT04403269Phase 2
- Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic SyndromeTerminatedNCT04402580Phase 2
- Using GM-CSF as a Host Directed Therapeutic Against COVID-19CompletedNCT04400929Phase 2
- Effects of Ocrevus in Relapsing Multiple SclerosisActive, not recruitingNCT04387734Phase 4
- Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With OcrelizumabCompletedNCT04377555Phase 4
- Low-dose Lenalidomide for Non-severe COVID-19 Treatment TrialStatus unknownNCT04361643Phase 4
- Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT04361409Phase 1
- A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCLCompletedNCT04361279Phase 3
- Convalescent Antibodies Infusion in Critically Ill COVID 19 PatientsTerminatedNCT04346589Not applicable
- Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) TrialCompletedNCT04324463Phase 3
- Study of Pidotimod in Children With Recurrent Respiratory Tract Infections (RRI)CompletedNCT04322669Phase 4
- Rituximab Combined With Chidamide and Lenalidomide for r/r AITLStatus unknownNCT04319601Not applicable
- rATG Versus rATG Combined With Intravenous Immunoglobulin (IVIG) Induction Immunosuppression in HLA Incompatible Transplantation (INHIBIT)CompletedNCT04302805Phase 3
- Frontline Lenalidomide for AL Amyloidosis Involving MyocardiumCompletedNCT04298372Phase 3
- Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple MyelomaWithdrawnNCT04288765Phase 3
- Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04287855Phase 2
- Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT04285268Phase 2
- A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCLWithdrawnNCT04279938Phase 1
- Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple MyelomaStatus unknownNCT04277845Phase 2
- Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to DaratumumabActive, not recruitingNCT04270175Phase 2
- Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint InhibitorsActive, not recruitingNCT04262466Phase 1/2
- The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected PneumoniaStatus unknownNCT04261426Phase 2/3
- Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic CancerCompletedNCT04257448Phase 1/2
- Rituximab at Low dosE for neuromyelitiS optiCa spectrUm disordEr (RESCUE)CompletedNCT04256252Phase 4
- Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell LymphomaStatus unknownNCT04246359Phase 2
- FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal AntibodiesTerminatedNCT04245722Phase 1
- Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and BortezomibTerminatedNCT04243109Phase 2
- Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell LymphomaStatus unknownNCT04231370Phase 2
- CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in ChildrenCompletedNCT04224571Phase 2
- A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.Active, not recruitingNCT04224493Phase 3
- Intravenous Immunoglobulins for Prevention of BKV Infection in Kidney Transplant Recipients According to BKV Genotype-specific Neutralizing Antibody Titers at the Day of Transplantation.CompletedNCT04222023Phase 4
- Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM PatientsCompletedNCT04217967Phase 4
- R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell LymphomaCompletedNCT04214626Phase 2
- A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone LymphomaActive, not recruitingNCT04212013Phase 3
- ATG in HLA-matched Sibling HSCT as GVHD ProphylaxisStatus unknownNCT04203108Phase 4
- TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and SurgeryStatus unknownNCT04197687Phase 2